Specialist managers see more shorting activity

James Fiore, primary manager of the Life Science Group Partners sector hedge fund, says the biotech and pharmaceutical-focused fund is presently 'predominantly in biotechnology' as the industry has had 'its worst bear market ever and is over 45% down for the year.'

Fiore says: 'Biotech is dominated in the US by individual investors and they're very skittish at the moment, so finding value in the sector is like shooting fish in a barrel.' He adds that a lot of biotechs are trading at levels below

Only users who have a paid subscription or are part of a corporate subscription are able to print or copy content.

To access these options, along with all other subscription benefits, please contact info@risk.net or view our subscription options here: http://subscriptions.risk.net/subscribe

You are currently unable to copy this content. Please contact info@risk.net to find out more.

Sorry, our subscription options are not loading right now

Please try again later. Get in touch with our customer services team if this issue persists.

New to Risk.net? View our subscription options

You need to sign in to use this feature. If you don’t have a Risk.net account, please register for a trial.

Sign in
You are currently on corporate access.

To use this feature you will need an individual account. If you have one already please sign in.

Sign in.

Alternatively you can request an individual account here